Cover Image

Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial

Treatment options for patients with advanced hepatocellular carcinoma (HCC) are often limited. In most cases, they are not amenable to local therapies including surgery or radiofrequency ablation. The multi-kinase inhibitor sorafenib has shown to increase overall survival in this patient group for a...

Full description

Saved in:
Bibliographic Details
Main Authors: Combs, Stephanie (Author) , Habermehl, Daniel (Author) , Ganten, Tom M. (Author) , Schmidt, Jan (Author) , Edler, Lutz (Author) , Burkholder, Iris (Author) , Jäkel, Oliver (Author) , Haberer, Thomas (Author) , Debus, Jürgen (Author)
Format: Article (Journal)
Language:English
Published: 12 February 2011
In: BMC cancer
Year: 2011, Volume: 11, Pages: 1-8
ISSN:1471-2407
DOI:10.1186/1471-2407-11-67
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-11-67
Verlag, lizenzpflichtig, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-67
Get full text
Author Notes:Stephanie E. Combs, Daniel Habermehl, Tom Ganten, Jan Schmidt, Lutz Edler, Iris Burkholder, Oliver Jäkel, Thomas Haberer, Jürgen Debus
Description
Summary:Treatment options for patients with advanced hepatocellular carcinoma (HCC) are often limited. In most cases, they are not amenable to local therapies including surgery or radiofrequency ablation. The multi-kinase inhibitor sorafenib has shown to increase overall survival in this patient group for about 3 months.
Item Description:Im Titel wird die Zahl eins als römische Ziffer bzw. als klein geschriebenes "i" dargestellt
Gesehen am 08.04.2022
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-11-67

Similar Items